Credit Suisse’s Recursion Pharmaceuticals RXRX Stock Holding History

Credit Suisse’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$19.3M	Buy	1,936,970 +234,914	+14%	+$2.62M	0.02%	643
2023 Q4	$16.8M	Buy	1,702,056 +15,170	+0.9%	+$108K	0.02%	712
2023 Q3	$12.9M	Sell	1,686,886 -13,005	-0.8%	-$130K	0.01%	801
2023 Q2	$12.7M	Buy	1,699,891 +117,518	+7%	+$822K	0.01%	823
2023 Q1	$10.6M	Buy	1,582,373 +6,783	+0.4%	+$53.8K	0.01%	913
2022 Q4	$12.1M	Buy	1,575,590 +10,235	+0.7%	+$100K	0.01%	844
2022 Q3	$16.7M	Buy	1,565,355 +302	+0%	+$3.06K	0.02%	723
2022 Q2	$12.7M	Buy	1,565,053 +451	+0%	+$3.02K	0.01%	849
2022 Q1	$11.2M	Buy	1,564,602 +4,984	+0.3%	+$53K	0.01%	999
2021 Q4	$26.7M	Buy	1,559,618 +109,022	+8%	+$2.05M	0.01%	948
2021 Q3	$33.4M	Buy	1,450,596 +1,011	+0.1%	+$28.7K	0.02%	822
2021 Q2	$52.9M	Buy	+1,449,585	New	+$42.9M	0.03%	649

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse's RXRX Position: Q1 2024 in Review

Credit Suisse increased its Recursion Pharmaceuticals (RXRX) stake by 14% in Q1 2024, buying an estimated $2.62M and bringing the position to 1,936,970 shares worth $19.3M. The position accounts for 0.02% of the portfolio, ranked #643.

Credit Suisse first reported a position in RXRX in Q2 2021 and has held it in 12 quarters since. The position peaked at $52.9M in Q2 2021. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

Credit Suisse held 1,936,970 shares of Recursion Pharmaceuticals worth $19.3M as of Q1 2024.
Credit Suisse bought 234,914 Recursion Pharmaceuticals shares in Q1 2024, an estimated $2.62M.
Recursion Pharmaceuticals made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #643 holding.
Credit Suisse first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
Credit Suisse's Recursion Pharmaceuticals position peaked at $52.9M in Q2 2021.
249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.